Transgene SA (TNG)

Overview

Transgene SA is a pioneering biotechnology company based in Illkirch-Graffenstaden, France, with a dedicated focus on the development of innovative therapeutic vaccines and oncolytic viruses aimed at treating cancer. Established in 1979, the company leads the way in its field by employing advanced biotechnological methods to engineer novel treatments that stimulate the immune system to combat cancerous cells. With a significant portfolio of products in various stages of clinical trials, Transgene SA is at the forefront of bringing next-generation cancer therapies to patients worldwide. As a subsidiary of TSGH SAS, Transgene SA benefits from a strong backing that supports its mission to advance cancer treatment. Through strategic collaborations with leaders in the pharmaceutical and biotechnology industries including AstraZeneca, Merck KGaA, Pfizer, NEC Corporation, and others, Transgene is expanding its reach and accelerating the development of its innovative therapeutic solutions.

Products and Services

• TG4050

  A therapeutic vaccine currently in Phase I clinical trial designed for the treatment of ovarian cancer and head and neck cancers. TG4050 represents Transgene's commitment to advancing personalized cancer immunotherapy, leveraging cutting-edge technology to tailor treatments specific to the genetic makeup of a patient's tumor.

• TG4001

  This therapeutic vaccine, in Phase II clinical trial, targets HPV-positive cancers. It reflects Transgene's efforts to combat cancers caused by human papillomavirus (HPV), emphasizing the company's role in addressing viral-induced malignancies through innovative vaccine technology.

• TG6002

  An oncolytic virus in Phase I/IIa clinical trial designed for the treatment of gastrointestinal and colorectal cancers. TG6002 showcases Transgene's expertise in engineering viruses that selectively infect and destroy cancer cells, offering a promising approach to treating these types of cancers.

• BT-001

  Currently in Phase I/II clinical trial, this oncolytic virus is developed for the treatment of solid tumors. BT-001 exemplifies the innovative approach of combining oncolytic virus therapy with immune checkpoint blockade to enhance the immune system's ability to fight cancer.

• TG1050

  A therapeutic vaccine aimed at treating hepatitis B, illustrating Transgene's approach to leveraging its vaccine platform technology beyond cancer, to address chronic viral infections that pose significant health risks worldwide.

• TG6050

  Designed for the treatment of non-small cell lung cancer, TG6050 represents another facet of Transgene’s diverse pipeline, focusing on one of the most common and lethal cancer types with a novel therapeutic vaccine approach.

• Pexa-Vec

  An oncolytic virus developed for the treatment of solid tumors. Pexa-Vec is part of Transgene's broader portfolio of oncolytic viral therapies, demonstrating the company's commitment to exploring and harnessing the power of viruses as allies in the fight against cancer.